Wikipedia
Mogamulizumab
Mogamulizumab ( USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It was approved in Japan in 2012 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.
Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd. It has also been licensed to Amgen for development as a therapy for Asthma.
In 2016 it was in phase 1 clinical trials (in combination with utomilumab(PF-05082566)) for solid cancers.